Cipla Ltd share price logo

Cipla Ltd Share Price

(CIPLA)

₹1515.21.26%

as on 04:01PM, 17 Apr 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Cipla Performance

  • Day's Low

    Day's High

    ₹1,486
    Day's Price Range
    ₹1,522
  • 52 Week's Low

    52 Week's High

    ₹1,317.25
    52-Week Price Range
    ₹1,702.05
1 Month Return+ 0.43 %
3 Month Return+ 4.83 %
1 Year Return+ 12.46 %
Previous Close₹1,496.40
Open₹1,498.00
Volume12.12L
Upper Circuit₹1,646.00
Lower Circuit₹1,346.80
Market Cap₹1,22,370.15Cr

Cipla Fundamentals

P/E Ratio

24.52

PEG Ratio

1.55

Market Cap

₹1,22,370.15 Cr

P/B Ratio

4.31

EPS

51.47

Dividend Yield

0.87

Sector

Pharmaceuticals

ROE

15.5

Cipla Analyst Rating

based on 37 analysts

BUY

64.86%

Buy

21.62%

Hold

13.51%

Sell

Based on 37 analysts offering long term price targets for Cipla. An average target of ₹1642.27

Source: S&P Global Market Intelligence

Cipla Share analysis

Cipla price forecast by 37 analysts

Upside of8.39%

High

₹1875

Target

₹1642.27

Low

₹1204

Cipla target price ₹1642.27, a slight upside of 8.39% compared to current price of ₹1515.2. According to 37 analysts rating.

Source: S&P Global Market Intelligence

Key events for Cipla Ltd

  • Cipla's Medispray Facility Receives VAI Classification - 18 Apr, 2025

    Cipla Ltd announced that its Medispray Laboratories facility in Goa received a Voluntary Action Indicated (VAI) classification from the USFDA, indicating non-critical issues. The company views this as part of its commitment to good governance practices.
  • Nomura Reaffirms Buy Rating on Cipla with Target Price - 14 Apr, 2025

    Nomura maintains a 'Buy' rating on Cipla Ltd, setting a target price of Rs 1,780 by March 2026. The approval of gAbraxane by the USFDA enhances Cipla's market visibility, with expected revenues of $18 million and $56 million for FY26 and FY27, respectively. Despite competition, Cipla is anticipated to capture significant market share.
  • Cipla Secures USFDA Approval for Generic Cancer Drug - 11 Apr, 2025

    Cipla Limited received final USFDA approval for its generic version of Abraxane, enhancing its oncology portfolio. The product is expected to launch in the first half of FY 2025-26, leading to a 5% share price increase.
  • Cipla Secures FDA Approval and Announces Earnings Date - 10 Apr, 2025

    Cipla has received USFDA approval for Lanreotide injection, marking a significant milestone for its US business. Additionally, the company announced its Q4 FY2025 earnings release date and potential dividend on May 13, 2025.
  • Cipla Reports Strong Q3 FY25 Financial Results - 08 Apr, 2025

    Cipla Ltd announced a revenue of Rs 7,073 crore and a net profit of Rs 1,575 crore for Q3 FY25, reflecting significant growth compared to the previous year.
  • Cipla Faces Pressure Amid Pharma Index Decline - 07 Apr, 2025

    Cipla's stock faced downward pressure as its share price contributed to the NSE Nifty Pharma index reaching its lowest level in over 10 months.
  • Cipla Shares Plummet Amid Tariff Concerns - 04 Apr, 2025

    Cipla Ltd's shares fell 6.08% due to concerns over potential U.S. pharmaceutical tariffs announced by President Trump, impacting investor sentiment significantly.
  • Cipla Shares Surge After U.S. Tariff Exemption - 03 Apr, 2025

    Cipla's stock gained significantly after the U.S. government exempted pharmaceuticals from new tariffs, providing relief to Indian generic drug exporters. The broader Nifty Pharma index also rallied, reflecting positive market sentiment.
  • Concerns Over US Tariffs Impacting Indian Pharma - 30 Mar, 2025

    India's pharma sector faces challenges due to a 10% tariff on US imports, raising concerns among industry groups about the financial burden on distributors and generic manufacturers.
  • Cipla's Nifty Weightage Increase Expected - 26 Mar, 2025

    Cipla is anticipated to see an increase in its weightage in the Nifty 50 index, leading to an inflow of approximately $29 million.
  • Cipla Positioned for Growth Amid Challenges - 22 Mar, 2025

    Cipla faces moderate headwinds but is well-positioned for long-term growth with a strong product pipeline and strategic consolidation in Africa. The stock is recommended for accumulation at current valuations.

Insights on Cipla Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, 939.04 Cr → 1.57K Cr (in ₹), with an average increase of 15.6% per quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 17.44% to 20.42% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 6.41K Cr → 7.29K Cr (in ₹), with an average increase of 4.2% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, CIPLA stock has moved up by 4.8%

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 16.08% to 16.41% in Dec 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 52.1% return, outperforming this stock by 39.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 128.1% return, outperforming this stock by 80.7%

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 30.86% to 29.13% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 28.74% to 26.60% in Dec 2024 quarter

Cipla News

RBI Imposes Fines on Kotak Mahindra, IDFC First, and Punjab National Bank

Kotak Mahindra Bank, one of the leading private banks, faced the stiffest penalty among the three. The RBI levied a Rs 61.40 lakh fine for non-compliance with certain directions on Guidelines on Loan System for Delivery of Bank Credit and Loans and Advances – Statutory and Other Restrictions, reported Economic Times. The bank was reportedly penalised for irregularities in the sanctioning and distribution of working capital limits to borrowers, and non-compliance in margin requirements for intraday trading limits granted to select stockbrokers.18 Apr, 2025 12:39 PM

RBI Levies Penalties on Kotak Mahindra Bank, IDFC First, PNB

The Reserve Bank of India (RBI) has imposed financial penalties on three major banks—Kotak Mahindra Bank, IDFC First Bank, and Punjab National Bank—owing to identified shortcomings in regulatory compliance. Kotak Mahindra Bank received the highest penalty of Rs 61.4 lakh for violations concerning the Guidelines on Loan System for Delivery of Bank Credit and other statutory restrictions.18 Apr, 2025 08:55 AM

Kotak Mahindra Bank and Others Fined by RBI for Regulatory Non-Compliance

a penalty of Rs 61.4 lakh has been levied on Kotak Mahindra Bank for non-compliance with specific provisions under the Guidelines on Loan System for Delivery of Bank Credit and Loans and Advances – Statutory and Other Restrictions.17 Apr, 2025 08:49 PM
View More

Cipla Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹6,505.66Cr (-)₹6,082.37Cr (↓6.51%)₹6,624.86Cr (↑8.92%)₹6,961.22Cr (↑5.08%)₹6,961.60Cr (↑0.01%)
Net Income₹1,068.51Cr (-)₹934.40Cr (↓12.55%)₹1,176.29Cr (↑25.89%)₹1,306.02Cr (↑11.03%)₹1,583.72Cr (↑21.26%)
Net Profit Margin16.42% (-)15.36% (↓6.46%)17.76% (↑15.63%)18.76% (↑5.63%)22.75% (↑21.27%)
Value in ₹ crore
Details2021202220232024
Total Assets₹22,963.74Cr (-)₹25,683.49Cr (↑11.84%)₹27,846.42Cr (↑8.42%)₹31,264.30Cr (↑12.27%)
Total Liabilities₹3,036.18Cr (-)₹3,169.94Cr (↑4.41%)₹3,208.33Cr (↑1.21%)₹3,290.38Cr (↑2.56%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹2,018.14Cr (-)₹3,460.31Cr (↑71.46%)₹2,773.43Cr (↓19.85%)₹3,035.05Cr (↑9.43%)₹3,726.77Cr (↑22.79%)

Cipla Index Inclusions

Nifty50 Value 20

₹12,362.05

1.29 (156.85%)

S&P BSE 100 LargeCap TMC

₹8,805.50

1.6 (138.27%)

Nifty100 Low Volatility 30

₹19,114.40

1.2 (225.9%)

BSE MFG

₹971.55

0.99 (9.57%)

NIFTY PHARMA

₹21,126.75

1.21 (252.45%)

S&P BSE Largecap

₹9,178.08

1.58 (142.8%)

Nifty LargeMidcap 250

₹15,053.65

1.08 (161.05%)

BSE 100

₹24,934.68

1.55 (380.07%)

Nifty100 Eq Weig

₹30,858.60

1.02 (312.45%)

BSE 500

₹34,109.67

1.3 (439.36%)

NIFTY 50

₹23,851.65

1.77 (414.45%)

BSE Healthcare

₹41,697.12

0.91 (377.9%)

S&P BSE 250 LargeMidCap

₹10,181.09

1.4 (140.44%)

S&P BSE Dividend Stability

₹958.58

0.75 (7.09%)

Nifty 200

₹13,186.10

1.42 (185.1%)

Nifty 500

₹21,681.55

1.3 (277.2%)

S&P BSE SENSEX 50

₹24,882.50

1.76 (429.71%)

BSE 200

₹10,763.75

1.44 (152.51%)

Nifty Healthcare

₹13,711.05

1.16 (157.55%)

S&P BSE 100 ESG

₹400.03

1.87 (7.34%)

NIFTY 100

₹24,418.35

1.59 (381.1%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Cipla Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
29.13%
-5.58
Foreign Institutions
26.6%
-7.45
Mutual Funds
20.42%
17.09
Retail Investors
16.41%
2.06
Others
7.44%
8.01

Cipla Key Indicators

Details20202021202220232024
Return On Equity %13.9713.2213.9410.6615.5
Details20202021202220232024
Return On Assets %7.4910.479.810.0613.18
Details20202021202220232024
Book Value Per Share (₹)195.51227.25258.33290.01330.79
Details20202021202220232024
Earning Per Share (₹)19.1929.7831.7235.1351.47

Cipla Valuation

Cipla in the last 5 years

  • Overview

  • Trends

Lowest (18.11x)

March 19, 2020

Today (24.52x)

April 17, 2025

Industry (53.02x)

April 17, 2025

Highest (42.80x)

January 23, 2018

LowHigh

Cipla Earnings and Dividends

  • Cipla Ltd Earnings Results

    Cipla Ltd’s net profit jumped 48.74% since last year same period to ₹1,570.51Cr in the Q3 2024-2025. On a quarterly growth basis, Cipla Ltd has generated 20.57% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Cipla Ltd Dividends May,2024

    In the quarter ending March 2024, Cipla Ltd has declared dividend of ₹13 - translating a dividend yield of 1.42%.

    Read More about Dividends

Cipla Technicals Summary

Bearish

Neutral

Bullish

Bullish

Cipla Ltd is currently in a Bullish trading position according to technical analysis indicators.

Cipla Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹1,22,370.15 Cr31.77%0.50₹4,155 Cr₹25,774 Cr
HOLD₹1,49,724.28 Cr28.15%0.50₹1,600 Cr₹7,845 Cr
BUY₹1,10,152.27 Cr35.85%0.67₹1,656 Cr₹10,727 Cr
BUY₹39,775.88 Cr-1.49%0.58₹1,297 Cr₹14,755 Cr
HOLD₹23,879.80 Cr-4.07%0.50₹772 Cr₹5,664 Cr

About Cipla

Cipla Ltd is an Indian multinational pharmaceutical and biotechnology company founded in 1935 by Dr. K.A. Hamied. It is headquartered in Mumbai, India and is one of the leading pharmaceutical companies in the world. Cipla has over 35000 employees and is present in 80+ countries. The company has a diversified product portfolio that includes active pharmaceutical ingredients (API), generics, OTC products, biosimilars, and nutraceuticals.

Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.

Revenue: ₹6,961.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,583.72Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
OrganisationCipla
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Cipla Ltd

What is Cipla Ltd price today?

Cipla Ltd share price today stands at ₹1515.2, Open: ₹1498, Previous Close: ₹1496.4, High: ₹1522, Low: ₹1486, 52 Week High: ₹1702.05, 52 Week Low: ₹1317.25.

How to Buy Cipla Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Cipla Ltd shares

What are today's traded volumes of Cipla Ltd?

Today's traded volume of Cipla Ltd(CIPLA) is 12.12L.

What is today's market capitalisation of Cipla Ltd?

Today's market capitalisation of Cipla Ltd(CIPLA) is ₹122370.15Cr.

What is the 52 Week High and Low Range of Cipla Ltd?

Cipla Ltd (CIPLA)
Price
52 Week High
₹1702.05
52 Week Low
₹1317.25

How much percentage Cipla Ltd is down from its 52 Week High?

Cipla Ltd (CIPLA) share price is ₹1515.2. It is down -10.98% from its 52 Week High price of ₹1702.05

How much percentage Cipla Ltd is up from its 52 Week low?

Cipla Ltd (CIPLA) share price is ₹1515.2. It is up 15.03% from its 52 Week Low price of ₹1317.25